Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-13

Clinical Trial Update: Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough [Phase 2]

View source ↗

Summary

Phase 2 trial updating on efficacy and safety of BLU-5937 in adults with refractory chronic cough.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BLU-5937 (BLU-5937)

Snippet

Sponsor: Bellus Health Inc. - a GSK company | Conditions: Refractory Chronic Cough | Phase 2 | Status: COMPLETED